Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
Rhea-AI Summary
Lexicon Pharmaceuticals (Nasdaq: LXRX) reported Q1 2026 results and pipeline updates on May 7, 2026. Key points: Total revenue $21.1M (including a $20.0M Novo Nordisk milestone), cash, investments and restricted cash $199.7M, and a $100M Hercules loan facility with $55M funded.
Clinical highlights: SONATA-HCM enrollment expected mid-2026, potential NDA resubmission for ZYNQUISTA mid-2026, and Novo Nordisk initiated Phase 1 for LX9851.
Positive
- Total revenue of $21.1M in Q1 2026
- Received a $20.0M development milestone from Novo Nordisk
- $199.7M in cash, investments and restricted cash as of March 31, 2026
- Novo Nordisk initiated Phase 1 study of LX9851; Lexicon eligible for additional milestone payments
- $100M Hercules loan facility with initial $55M tranche funded
Negative
- Q1 2026 revenue driven primarily by a one-time $20.0M milestone, with INPEFA net sales of $1.1M
- Remaining $45M of Hercules tranches subject to clinical, regulatory or creditor consent
- Minimum cash covenant begins June 1, 2027, subject to milestone-based extensions
News Market Reaction – LXRX
In the May 7 session, LXRX gained 5.00%, reflecting a notable positive market reaction. Argus tracked a peak move of +18.9% during that session. Argus tracked a trough of -4.9% from its starting point during tracking. Our momentum scanner triggered 32 alerts that day, indicating elevated trading interest and price volatility. Trading volume was very high at 3.6x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 05 | Q4 2025 earnings | Positive | +0.6% | Reported Q4/FY 2025 results and pipeline progress with $49.8M full-year revenue. |
| Nov 06 | Q3 2025 earnings | Positive | +3.6% | Q3 revenue jump to $14.2M and reduced net loss, plus key R&D milestones. |
| Aug 06 | Q2 2025 earnings | Positive | +9.5% | Recorded $3.3M net income and $28.9M revenue with strong pipeline updates. |
| May 13 | Q1 2025 earnings | Positive | -15.6% | Announced Novo Nordisk deal and PROGRESS data alongside modest Q1 revenues. |
| Mar 06 | FY 2024 earnings | Positive | +6.5% | Q4 2024 revenue rose to $26.6M with positive pilavapadin Phase 2b results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings releases have generally seen modestly positive price reactions, with one notable negative divergence.
Over the past year, Lexicon’s earnings reports have highlighted a shift from large losses toward tighter net results and improved revenue, aided by milestone payments and partnerships. Prior quarters showed growing contributions from Novo Nordisk and Viatris and steady progress in SONATA-HCM, ZYNQUISTA, pilavapadin and LX9851. Today’s Q1 2026 update, with higher revenues, a much smaller net loss, and reinforced liquidity, continues this pattern of operational and pipeline advancement.
Key Terms
nda regulatory
phase 3 medical
phase 1 medical
hypertrophic cardiomyopathy medical
acyl-coa synthetase 5 (acsl5) medical
average daily pain score (adps) medical
placebo-controlled medical
new drug application regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SONATA-HCM anticipated to be fully enrolled mid-2026
Resubmission of NDA for ZYNQUISTA® in type 1 diabetes anticipated mid-2026 with potential for approval this year
Clinical development of LX9851 initiated by Novo Nordisk
Capital raise, development milestone payments, and recent
Conference call and webcast at 8:30 am ET
THE WOODLANDS, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2026, and provided an update on key corporate milestones and accomplishments.
“We have been intently focused on progressing our late and early-stage development pipeline in cardiometabolism and we are now well positioned to achieve several pivotal milestones as a result of those efforts,” said Mike Exton, Ph.D., Lexicon’s chief executive officer and director. “Over the next 12 months, those events potentially include the announcement of topline data from our ongoing registrational trial of sotagliflozin in hypertrophic cardiomyopathy, U.S. regulatory approval of ZYNQUISTA as the first adjunct to insulin for glycemic management in people with type 1 diabetes and the completion of initial Phase 1 development of LX9851 by our licensee, Novo Nordisk. Taken together, we believe these events have the potential to be transformative for Lexicon’s future.”
“Following our capital raise, receipt of two development milestones from Novo Nordisk earlier this year and our recently announced loan facility, our operations are now underpinned by a strengthened balance sheet,” said Scott Coiante, Lexicon’s chief financial officer, “We remain focused on disciplined capital allocation as we continue to advance our clinical programs and seek to maximize long-term shareholder value.”
First Quarter 2026 Business and Pipeline Highlights
Cardiometabolic
Sotagliflozin
Sotagliflozin is an oral inhibitor of sodium-glucose cotransporter types 1 and 2 (SGLT1 and SGLT2) and has been studied in approximately 20,000 patients across multiple cardiometabolic indications. Sotagliflozin is commercially available in the U.S. for heart failure as INPEFA®.
Hypertrophic Cardiomyopathy (HCM)
- Enrollment continues in SONATA-HCM, a pivotal Phase 3 placebo-controlled study with a targeted enrollment of 500 patients with obstructive or nonobstructive HCM.
- Lexicon continues to expect enrollment completion in mid-2026, with topline results in the first quarter of 2027.
Type 1 Diabetes (T1D) (ZYNQUISTA®)
- Lexicon remains focused on bringing ZYNQUISTA to market for glycemic control in adults with T1D, a patient population which has not benefitted from a new treatment mechanism since the discovery of insulin.
- Lexicon remains on track for potential New Drug Application (NDA) resubmission and regulatory approval in 2026 if the patient exposure and safety data requirements identified by the U.S. Food and Drug Administration are achieved by STENO1, a third-party funded, investigator-initiated study of sotagliflozin being conducted by the STENO Diabetes Center (Denmark).
Viatris License for All Indications Ex-U.S. and Ex-Europe
- Lexicon continues to support licensee Viatris in its regulatory filing and commercial strategy for sotagliflozin outside of the U.S. and Europe.
- Viatris has obtained regulatory approval in the United Arab Emirates, has submitted applications for regulatory approval in several other markets, including Canada, Australia and New Zealand, and is preparing for regulatory submissions in additional ex-U.S. and ex-European markets throughout 2026.
LX9851 for Obesity and Associated Cardiometabolic Disorders
LX9851 is a first-in-class, non-incretin, oral, small molecule inhibitor of acyl-CoA synthetase 5 (ACSL5) in development by Novo Nordisk for obesity and associated metabolic disorders.
- In March 2026, Novo Nordisk initiated a Phase 1 study investigating single and multiple ascending doses of LX9851 compared to placebo in overweight or obese people. The Phase 1 program is expected to be completed in the first quarter of 2027.
- Lexicon earned a second
$10 million milestone payment in 2026 from Novo Nordisk in connection with initiation of the Phase 1 study and is eligible for a third$10 million milestone payment that may be achieved later this year. - Under the terms of Lexicon’s exclusive license agreement with Novo Nordisk, Lexicon received an upfront payment of
$45 million in April 2025 and is eligible to receive up to an aggregate of$1 billion in upfront and development, regulatory and sales milestone payments. Lexicon is also eligible for tiered royalties on net sales of LX9851.
Pain
Pilavapadin (LX9211) for Diabetic Peripheral Neuropathic Pain (DPNP)
Pilavapadin is an orally delivered, small molecule drug candidate for the treatment of DPNP, among other potential indications. Pilavapadin has the potential to be the first oral, non-opioid drug therapy approved in neuropathic pain in more than 20 years.
- The FDA has raised no objections to the advancement of pilavapadin into Phase 3 development, which would include two placebo-controlled, 12-week, two arm registrational studies comparing the 10 mg daily dose to placebo. The primary endpoint of the Phase 3 studies would be the change in average daily pain score (ADPS) from baseline to Week 12.
- Lexicon continues to explore strategic opportunities to maximize the global potential of this investigative therapy.
Recent Data Presentations
Sotagliflozin
- In March 2026, Lexicon presented results of a post hoc analysis of clinical data evaluating the impact of kidney function on the long-term efficacy and safety of sotagliflozin in people with T1D at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). The analysis concluded that sotagliflozin improved glycemic control after one year in patients with normal and mildly reduced kidney function.
- In March 2026, Lexicon presented three analyses from the SCORED and SOTA-P-CARDIA studies of sotagliflozin at the American College of Cardiology (ACC) Annual Meeting. The data provided further evidence of benefits of sotagliflozin across patient subgroups potentially related to its mechanism of action.
Pilavapadin
- In April 2026, Lexicon presented additional pilavapadin clinical data at the American Academy of Neurology (AAN) Annual Meeting, including additional data from the PROGRESS Phase 2b study supporting the selection of pilavapadin 10 mg as the optimal dose for Phase 3 development in DPNP, as well as an evaluation of pilavapadin as a potential novel, oral therapy for spasticity based on spasticity-related endpoints in preclinical models of multiple sclerosis and spinal cord injury.
First Quarter 2026 Financial Highlights
Revenues: Total revenues were
Total revenues for the first quarter of 2025 were
Research and Development (R&D) Expenses: Research and development expenses for the first quarter of 2026 decreased to
Selling, General and Administrative (SG&A) Expenses: Selling, general and administrative expenses for the first quarter of 2026 decreased to
Net Loss: Net loss for the first quarter of 2026 was
Cash, Investments, and Restricted Cash: As of March 31, 2026, Lexicon had
Hercules Capital Loan Facility
In May 2026, Lexicon announced a
The loan facility carries a floating interest rate equal to the prime rate plus
Lexicon’s obligations under the loan facility are subject to a minimum cash covenant beginning on June 1, 2027, subject to extension upon the achievement of certain clinical, regulatory and financial milestones and waiver upon the achievement of certain financial conditions.
Conference Call and Webcast Information
Lexicon management will hold a live conference call and webcast today at 8:30 am ET / 7:30 am CT to review its financial and operating results and to provide a general business update. A live audio webcast of the call can be accessed by visiting the Events page of the Company’s investor relations website at https://investors.lexpharma.com/. Participants who wish to ask a question may join by phone at 800-715-9871 and use passcode 9826247. An archived version of the webcast will be available on the website for 30 days.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of regulatory filings for, and potential therapeutic and commercial potential of its other drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
For Media Inquiries:
Dave Belian
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
For Investor Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
| Lexicon Pharmaceuticals, Inc. | ||||||||
| Selected Financial Data | ||||||||
| Consolidated Statements of Operations Data | Three Months Ended March 31, | |||||||
| (In thousands, except per share data) | 2026 | 2025 | ||||||
| (Unaudited) | ||||||||
| Revenues: | ||||||||
| Net product revenue | $ | 1,090 | $ | 1,262 | ||||
| Licensing and milestone revenue | 20,000 | — | ||||||
| Royalties and other revenue | 12 | — | ||||||
| Total revenues | 21,102 | 1,262 | ||||||
| Operating expenses: | ||||||||
| Cost of sales | 108 | 30 | ||||||
| Research and development, including stock-based | ||||||||
| compensation of | 12,756 | 15,303 | ||||||
| Selling, general and administrative, including stock-based | ||||||||
| compensation of | 9,234 | 11,608 | ||||||
| Total operating expenses | 22,098 | 26,941 | ||||||
| Loss from operations | (996 | ) | (25,679 | ) | ||||
| Interest and other expense | (1,590 | ) | (1,835 | ) | ||||
| Interest income and other | 1,543 | 2,219 | ||||||
| Net loss | $ | (1,043 | ) | $ | (25,295 | ) | ||
| Net loss per common share, basic and diluted | $ | ( - | ) | $ | (0.07 | ) | ||
| Weighted average common shares outstanding, | ||||||||
| basic and diluted | 400,240 | 362,073 | ||||||
| As of | As of | |||||||
| Consolidated Balance Sheet Data | March 31, 2026 | December 31, 2025 | ||||||
| (In thousands) | ||||||||
| Cash and investments | $ | 170,658 | $ | 96,230 | ||||
| Restricted cash | 29,000 | 29,000 | ||||||
| Property and equipment, net | 1,753 | 1,863 | ||||||
| Goodwill | 44,543 | 44,543 | ||||||
| Total assets | 268,819 | 184,987 | ||||||
| Current portion of long-term debt | — | 4,595 | ||||||
| Long-term debt, net | 49,684 | 49,408 | ||||||
| Accumulated deficit | (2,018,626 | ) | (2,017,583 | ) | ||||
| Total stockholders' equity | 202,856 | 107,538 | ||||||
